Omega TherapeuticsOMGA
About: Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
Employees: 94
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more call options, than puts
Call options by funds: $33K | Put options by funds: $11K
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
4.23% less ownership
Funds ownership: 91.78% [Q2] → 87.55% (-4.23%) [Q3]
20% less funds holding
Funds holding: 66 [Q2] → 53 (-13) [Q3]
44% less capital invested
Capital invested by funds: $105M [Q2] → $58.9M (-$45.9M) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
62% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 21
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler Edward Tenthoff 48% 1-year accuracy 16 / 33 met price target | 344%upside $4 | Overweight Maintained | 15 Nov 2024 |